Worldwide Clinical Trials appoints vp, Oncology Medical Affairs
Gerald Messerschmidt joins firm from Talon Therapeutics
Messerschmidt has more than 20 years’ clinical and operational leadership in the development of critical therapies for a multitude of oncology indications, the firm said. His portfolio of experience includes small molecules, biologic products, medical devices, genetic modification of living organisms and immune modulation therapy.
Prior to joining Worldwide Clinical Trials, Messerschmidt held the position of vp, Clinical Development at Talon Therapeutics (formerly Hana Biosciences) where he co-led the successful development of Marqibo, a new liposome plus vincristine product. From 2008–2010, Messerschmidt held senior positions within oncology at Onyx Pharmaceuticals and Icon Clinical Research, preceded by leading Wild-Type Enterprises as chairman and ceo from 2000–2008.
You may also like
Regulatory
Grifols gets nod from European Medicines Agency for entire value chain of Grifols Egypt
The institution's certification endorses the entire plasma value chain under the highest European standards and opens the door for Egypt to, once domestic needs are met, export to other markets including Europe
Regulatory
Regulating innovation: a new focus on digital mental health technologies (DMHTs)
IMed Consultancy’s Benjamin Austin provides a clear understanding of how digital mental health technologies are innovating care and describes the evolving regulatory frameworks that ensure their safety and effectiveness
Regulatory
ten23 health QC lab to support commercial product testing for US customer following FDA approvals
This pivotal regulatory milestone enables FDA-compliant release and stability testing for injectable drug products throughout the clinical and commercial phases, in addition to manufacturing the commercial product